Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy
Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy and maintains $850 price target.
News & Forecast & Price target & Analyst Ratings & Estimates
Eli Lilly and Company (NYSE: LLY) unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Truist Securities analyst Robyn Karnauskas reiterates Eli Lilly and Co with a Buy and maintains $850 price target.
JP Morgan analyst Chris Schott maintains Eli Lilly and Co with a Overweight and raises the price target from $775 to $850.
Eli Lilly and Company’s (LLY) phase 3 clinical trial of tirzepatide in obstructive sleep apnea is likely to miss consensus expectations given the gender imbalance in the study, but could still meet study endpoints, UBS said in a note Thursday. The investment bank said it expects a 12% to 14% weight loss and a 30% to 37% reduction in the apnea-hypopnea index, or AHI, compared with the Street consensus for 20% weight loss and over 50% AHI reduction from baseline. “We think gender imbalances are the main culprit as it’s well-documented females disproportionately lose more weight than males,” UBS said in the note. Males make up 70% of the trial participants, while females account for the remaining 30%, according to the note. The firm maintained its buy rating on the company’s stock with a 12-month price target of $910.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We add Eli Lily and Company (LLY) to CFRA’s High-Quality Capital Appreciation Portfolio. LLY is one of the largest U.S. drug makers in terms of revenue and is a leading developer of drugs in a wide range of therapeutic areas such as endocrinology, which includes a diabetes drug portfolio that generates more than half of its total revenue. We are increasingly optimistic on LLY’s many ongoing efforts, including late-stage therapies such as donanemab (for Alzheimer’s disease), pirtobrutinib (for certain forms of leukemia and lymphoma), and tirzepatide (for sleep apnea and cardiology). Such innovation could complement LLY’s 10 key current drugs, which represent the majority of LLY’s total sales. LLY replaces CVS Health Corporation, which was downgraded to a Hold recommendation.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We add Eli Lily and Company (LLY) to CFRA’s High-Quality Capital Appreciation Portfolio. LLY is one of the largest U.S. drug makers in terms of revenue and is a leading developer of drugs in a wide range of therapeutic areas such as endocrinology, which includes a diabetes drug portfolio that generates more than half of its total revenue. We are increasingly optimistic on LLY’s many ongoing efforts, including late-stage therapies such as donanemab (for Alzheimer’s disease), pirtobrutinib (for certain forms of leukemia and lymphoma), and tirzepatide (for sleep apnea and cardiology). Such innovation could complement LLY’s 10 key current drugs, which represent the majority of LLY’s total sales. LLY replaces CVS Health Corporation, which was downgraded to a Hold recommendation.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $56 to $885, reflecting 57.0x our 2025 EPS, justified by LLY’s robust revenue and earnings growth outlook. We lift our 2024 EPS estimate by $0.10 to $12.50 and our 2025 view by $0.06 to $15.53. Leaving behind a year of robust performance in 2023 with top-line revenue growth of 28% Y/Y, we think LLY will continue to outperform peers. We see superior growth prospects for Eli Lilly in the next two years in an environment where competitors will see slower growth and more limited cushion against key drugs’ loss of exclusivities. We updated our model and now expect 2024 revenue growth of 21% Y/Y and another 14% Y/Y in 2025, while we expect record EPS growth of 98% Y/Y and 24%…
Read More “CFRA Retains Strong Buy Opinion On Shares Of Eli Lilly And Company” »
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/20/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/16/2024 25.58% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 7.73% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.36% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.41% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.07% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.34% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.05% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 7.73% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -7.47% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.72% Cantor Fitzgerald → $630 Reiterates Overweight →…
Read More “Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings” »
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 21.39% Morgan Stanley $805 → $950 Maintains Overweight 02/14/2024 4.14% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 8.61% Truist Securities $650 → $850 Maintains Buy 02/07/2024 2.86% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 3.5% Barclays $680 → $810 Maintains Overweight 02/07/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 10.53% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 5.42% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 4.14% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -10.56% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -19.5% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -13.11% Barclays $630 → $680 Maintains Overweight 12/21/2023…
Read More “Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings” »
Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/14/2024 8.29% Cantor Fitzgerald → $815 Reiterates Overweight → Overweight 02/07/2024 12.94% Truist Securities $650 → $850 Maintains Buy 02/07/2024 6.96% Morgan Stanley $763 → $805 Maintains Overweight 02/07/2024 7.62% Barclays $680 → $810 Maintains Overweight 02/07/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/07/2024 14.93% BMO Capital $710 → $865 Maintains Outperform 02/06/2024 9.62% Wells Fargo $700 → $825 Maintains Overweight 02/06/2024 8.29% Cantor Fitzgerald $630 → $815 Maintains Overweight 02/05/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 02/01/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/24/2024 -6.99% Wells Fargo $650 → $700 Maintains Overweight 01/23/2024 -16.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 01/23/2024 -9.65% Barclays $630 → $680 Maintains Overweight 12/21/2023 -18.95% Daiwa Capital → $610 Downgrades Buy → Outperform…
Read More “Eli Lilly and Co (NYSE:LLY) Stock Analyst Ratings” »
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $815 price target.